ArticleJournal of general internal medicine2026
Timely Receipt of New Medication Treatment After Acute Care Encounters for Opioid Overdose in the U.S. Medicaid Population.
Article in Journal of general internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAcute care encounters for opioid overdose are increasingly recognized as critical opportunities to connect patients to opioid use disorder (OUD) treatment. However, national data on receipt of medication for OUD (MOUD) after overdose events are limited, particularly for new MOUD initiation.
objectiveTo examine MOUD receipt and timing after emergency department or inpatient encounters for opioid overdose, including patient characteristics associated with new MOUD initiation.
designRetrospective analysis of 2014-2019 national Medicaid claims data.
participantsAcute care opioid overdose events among non-dual eligible Medicaid enrollees aged 18-64 with continuous enrollment during the 180-day (6-month) baseline period preceding the overdose. MAIN MEASURES: The primary outcome was any MOUD (buprenorphine, methadone, naltrexone) receipt in the 180 days after discharge. Baseline MOUD receipt was categorized by the proportion of days covered (PDC): none (reference), very low (> 0 to < 20%), low (20 to < 50%), moderate (50 to < 80%), high (≥ 80%). KEY
resultsOf 318,536 opioid overdose events, 22.8% and 26.0% had MOUD in the 6 months before and after the event, respectively. Prior MOUD had the strongest association with follow-up MOUD, with a gradient by baseline exposure levels. In Cox models adjusting for patient sociodemographic and clinical covariates, overdose characteristics, and community-level factors, the likelihood of follow-up MOUD was 3.58 times higher for very low (95% CI = 3.50-3.66), 5.47 times higher for low (95% CI = 5.35-5.60), 7.36 times higher for moderate (95% CI = 7.17-7.56), and 16.35 times higher for high (95% CI = 15.92-16.80) baseline MOUD exposure compared to no prior MOUD. Timely follow-up MOUD within 30 days was also higher among those with (76.0%) than without (32.4%) prior MOUD.
conclusionsSubstantial gaps in MOUD receipt after opioid overdose indicate an urgent need to expand acute care interventions for treatment initiation, engagement, and referral as well as broader efforts to increase MOUD prescribing and uptake.
Identifiers
41530628What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.